34 related articles for article (PubMed ID: 23075630)
1. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
Wei YL; Xu L; Liang Y; Xu XH; Zhao XY
Acta Pharmacol Sin; 2009 Apr; 30(4):451-7. PubMed ID: 19270722
[TBL] [Abstract][Full Text] [Related]
2. LW-213, a newly synthesized flavonoid, induces G2/M phase arrest and apoptosis in chronic myeloid leukemia.
Liu X; Hu P; Li H; Yu XX; Wang XY; Qing YJ; Wang ZY; Wang HZ; Zhu MY; Guo QL; Hui H
Acta Pharmacol Sin; 2020 Feb; 41(2):249-259. PubMed ID: 31316178
[TBL] [Abstract][Full Text] [Related]
3. AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects.
Gayatri MB; Kancha RK; Behera A; Patchva D; Velugonda N; Gundeti S; Reddy ABM
Cell Death Discov; 2023 Oct; 9(1):401. PubMed ID: 37903788
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Patel YT; Jacus MO; Davis AD; Boulos N; Turner DC; Vuppala PK; Freeman BB; Gilbertson RJ; Stewart CF
Drug Metab Dispos; 2016 Apr; 44(4):591-4. PubMed ID: 26802130
[TBL] [Abstract][Full Text] [Related]
5. NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells.
McCune A; Kornbluth J
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201518
[TBL] [Abstract][Full Text] [Related]
6. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
[TBL] [Abstract][Full Text] [Related]
7. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia.
Piktel D; Moore JC; Nesbit S; Sprowls SA; Craig MD; Rellick SL; Nair RR; Meadows E; Hollander JM; Geldenhuys WJ; Martin KH; Gibson LF
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765664
[TBL] [Abstract][Full Text] [Related]
9. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Tilija Pun N; Jeong CH
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34065757
[TBL] [Abstract][Full Text] [Related]
10. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.
Guerra B; Recio C; Aranda-Tavío H; Guerra-Rodríguez M; García-Castellano JM; Fernández-Pérez L
Front Oncol; 2021; 11():626971. PubMed ID: 33718197
[TBL] [Abstract][Full Text] [Related]
11. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
Bencomo-Alvarez AE; Rubio AJ; Olivas IM; Gonzalez MA; Ellwood R; Fiol CR; Eide CA; Lara JJ; Barreto-Vargas C; Jave-Suarez LF; Nteliopoulos G; Reid AG; Milojkovic D; Druker BJ; Apperley J; Khorashad JS; Eiring AM
Oncogene; 2021 Apr; 40(15):2697-2710. PubMed ID: 33712704
[TBL] [Abstract][Full Text] [Related]
12. Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study.
Lu YC; Huang DW; Chen PT; Tsai CF; Lin MC; Lin CC; Wang SH; Pan YJ
Breast Cancer Res Treat; 2021 Feb; 185(3):773-783. PubMed ID: 33067779
[TBL] [Abstract][Full Text] [Related]
13. The Roles of Cholesterol and Its Metabolites in Normal and Malignant Hematopoiesis.
Oguro H
Front Endocrinol (Lausanne); 2019; 10():204. PubMed ID: 31001203
[TBL] [Abstract][Full Text] [Related]
14. Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.
Spindler SR; Mote PL; Flegal JM
Age (Dordr); 2016 Dec; 38(5-6):379-391. PubMed ID: 27590905
[TBL] [Abstract][Full Text] [Related]
15. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
[TBL] [Abstract][Full Text] [Related]
16. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Manu KA; Shanmugam MK; Li F; Chen L; Siveen KS; Ahn KS; Kumar AP; Sethi G
J Mol Med (Berl); 2014 Mar; 92(3):267-76. PubMed ID: 24233024
[TBL] [Abstract][Full Text] [Related]
18. G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol.
Yamada T; Park CS; Shen Y; Rabin KR; Lacorazza HD
Leuk Res; 2014 Feb; 38(2):210-7. PubMed ID: 24183236
[TBL] [Abstract][Full Text] [Related]
19. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
